GC
TXG icon

Guggenheim Capital’s 10x Genomics TXG Stock Holding History

Guggenheim Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,059
Closed -$221K – 2020
2022
Q4 		$221K Buy
+6,059
New +$198K ﹤0.01% 1773
2022
Q3 		– Sell
-5,710
Closed -$258K – 2049
2022
Q2 		$258K Buy
5,710
+519
+10% +$26.9K ﹤0.01% 1845
2022
Q1 		$395K Sell
5,191
-345
-6% -$30.2K ﹤0.01% 1768
2021
Q4 		$825K Buy
5,536
+1,948
+54% +$298K ﹤0.01% 1459
2021
Q3 		$523K Buy
3,588
+1,380
+63% +$237K ﹤0.01% 1726
2021
Q2 		$432K Buy
2,208
+262
+13% +$47.4K ﹤0.01% 1891
2021
Q1 		$352K Sell
1,946
-492
-20% -$85K ﹤0.01% 1892
2020
Q4 		$345K Buy
+2,438
New +$354K ﹤0.01% 1779

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Guggenheim Capital's TXG Position: Q1 2023 in Review

Guggenheim Capital sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 6,059 shares — an estimated $221K sold.

Guggenheim Capital first reported a position in TXG in Q4 2020 and held it in 8 quarters. The position peaked at $825K in Q4 2021. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • Guggenheim Capital reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • Guggenheim Capital sold 6,059 10x Genomics shares in Q1 2023, an estimated $221K.
  • Guggenheim Capital first reported a position in 10x Genomics in Q4 2020 and held it in 8 quarters.
  • Guggenheim Capital's 10x Genomics position peaked at $825K in Q4 2021.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.